Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

talix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx (TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease.  Protalix's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
For more information on Protalix, visit http://www.protalix.com.

Safe Harbor StatementTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements, including statements relating to the perceived effects of dual listing on the market for our common stock, are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Factors that might cause material differences include, among others, risks relating to the trading of our common stock on the Tel Aviv Stock Exchange or the NYSE Amex, risks relating to our continued compliance with the rules of the Tel Aviv Stock Exchange and the NYSE Amex and other
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... 31, 2014 North Shore Towers, a luxury ... with GI Energy, one of the nation’s leading combined heating ... upgrade of its 43-year-old CHP system. The original CHP system ... effort to extend the life of the plant, GI Energy ... electrical and heat recovery equipment, while maintaining continuous operation of ...
(Date:7/31/2014)... 31, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... the study of the genetic material or genomes of ... basis for the discovery and development of diagnostic and ... health conditions. Genomics is supported by three major product ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... ... Just Test Instruments , ... (Vocus) April 25, 2010 -- Responding to the recent rash of reports of quality failures ... consultations on how to develop and maintain strict gage R&R for entire assembly and test ...
... PLANO, Texas , April 27 A non-profit organization is ... the full amount of its corporate donations.  "Unlike Coca-Cola, Pepsi refuses to ... Greg Quinlan , President of Parents and Friends of Ex-Gays & ... , "This ...
... April 27 Two months after launching a strategic review of ... has signed an agreement to sell United Media Licensing for $175 million ... , , ... the family of the late Charles Schulz , who created the beloved ...
Cached Biology Technology:InterTech Service to Counter Widely Reported Problems in Automotive, Medical Device and Other Industries Requiring Rigorous Quality Standards 2Pepsi Urged to Follow Example of Coca-Cola and Stop Hiding Corporate Donations 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 2Scripps Announces Sale of United Media's Licensing Business for $175 Million 3
(Date:8/1/2014)... UC Davis Center for Neuroscience and Department of ... Engineering Faculty Fellowship from the U.S. Department of ... new work on learning and memory in Ranganath,s ... new project aims to connect neural oscillations, which ... cortex and hippocampus, brain regions that are known ...
(Date:8/1/2014)... Scientists examining a taxonomically confused group of marine ... science: the Australian humpback dolphin, Sousa sahulensis ... Clymene Enterprises. , The study describing the ... 17-year long systematic examination of all available historical ... dolphinsa widespread group of coastal cetaceans ranging from ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 15, 2013 A team of investigators systematically analyzed the ... in a rigorous and controlled study of postmenopausal women. They ... symptoms reported by the participants. Their results are published in ... . The influence of low calcium and vitamin D ...
... more soft drinks per capita than people in any ... of all ages, including very young children. Although ... suicidal thoughts in adolescents, the relationship had not been ... for publication in The Journal of Pediatric s ...
... 15, 2013) Primary results from a new ... diabetes treated with the monoclonal antibody teplizumab (MacroGenics, ... of islet cell function, compared to controls. Further ... group that demonstrated especially robust responses ("responders"), suggesting ...
Cached Biology News:Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women 2Soft drinks and behavioral problems in young children 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: